Sign In
Buy CGEM
$16.50
-1.02 (-5.82%)
At Close: Jul 31, 2026
TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass.
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
11:11pm, Thursday, 09'th Jan 2025
Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalerti
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
05:26pm, Wednesday, 08'th Jan 2025
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon 2
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
10:01am, Thursday, 14'th Nov 2024
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
07:00am, Tuesday, 05'th Nov 2024
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies,
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
07:00am, Monday, 04'th Nov 2024
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced
CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Na
Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
04:15am, Saturday, 14'th Sep 2024
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutat
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies,
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
07:00am, Saturday, 01'st Jun 2024
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progresse
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
08:00am, Friday, 24'th May 2024
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced t
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:05pm, Wednesday, 15'th May 2024
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
07:00am, Monday, 29'th Apr 2024
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appoin
